ISCT 2021 | Direct-to-consumer marketing of unproven orthopedic therapies

Nicolas Piuzzi, MD, Cleveland Clinic, Cleveland, OH, describes the current landscape of direct-to-consumer marketing of unproven orthopedic cell-based therapies, a major challenge facing the field of orthopedics that can put patients at risk, both medically and financially. Dr Piuzzi highlights the importance for international societies to continue to work together to provide reliable, unbiased information that patients can trust, allowing them to make informed treatment decisions. He notes that researchers and clinicians also have the responsibility to continue to advance research and conduct clinical effectiveness studies so that more therapies can be covered by health insurance. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.